Skip to content

Companies Reporting: Pets at Home, Salesforce, Dr Martens


Our regular look at the FTSE 350 and a selection of other companies reporting from 27-31 May 2024.

  • Pets at Home results expected to be in line with previously downgraded guidance
  • Can Salesforce reaccelerate top-line growth over the coming year?
  • Dr Martens looks to fix its US footprint

Pets at Home, Full Year Results, Wednesday 29 May

Guy Lawson-Johns, equity analyst, Hargreaves Lansdown: Pets at Home LON:PETS has shown that it isn’t immune to a challenging consumer environment. Downgraded profit guidance following a weak third quarter didn’t come as much of a surprise to investors, as inflationary pressures caused consumers to rein in their spending on more lucrative pet accessories.

Having largely shaken off the disappointment of slowing retail growth, investors will be hoping to be rewarded for their patience. In addition to looking for underlying profit before tax (PBT) of £132mn, markets will be eagerly awaiting forward-looking guidance. Utilising customer data insights and growing its online presence offer significant opportunities for growth, but these efforts don’t come cheap. Analysts are mindful that the group’s costs are growing and will be paying close attention to how investments will be sustainably funded.

Salesforce, Q1 Results, Wednesday 29 May

Matt Britzman, equity analyst, Hargreaves Lansdown: After a year of getting fit, Salesforce NYSE:CRM is a leaner beast ahead of first-quarter earnings. Margin progression last year was impressive and guidance points to further improvements over the coming year. But, without as many cost-cutting levers to pull, margin growth will need to come organically.

The macro-environment looks to have stabilised, and investors will now be looking for signs that subscription revenue growth can reaccelerate from the current c.10% guidance. AI will play a major part in that, and Salesforce is well-positioned to benefit given the amount of time customers spend on Slack, or its various other cloud products. But, with its Copilot tool still in beta mode and no benefit built into guidance for the coming year, it may take some time for AI to meaningfully drive top-line growth.

Dr. Martens, Full Year Results, Thursday 30 May

Derren Nathan, head of equity research, Hargreaves Lansdown: Dr. Martens’ LON:DOCS shareholders are nursing heavy losses and weakness in the US, its biggest market, continues to be a concern. The recent trading update suggests that we shouldn’t see too much divergence from consensus forecasts which expect revenue to fall by 11%, to under £0.9bn. That’s largely driven by expected weakness in the wholesale division. Analysts are looking for operating profit of £125mn, which would mark a fall of 34%.

The iconic bootmaker has outlined several challenges for this year. It’s anticipating another double-digit decline in US wholesale revenue. The decision to hold back on price increases means the company will be unable to offset inflation. Dr. Martens sees a potential two-thirds fall in pre-tax profits as the worst-case scenario but has not ruled out the possibility of an improvement. Markets will be watching out for further guidance.

This article has been brought to you in association with Hargreaves Lansdown. All opinions expressed in this article are from the analysts and do not necessarily represent the opinions of The Armchair Trader.

FTSE 100, FTSE 250 and selected other companies scheduled to report

No FTSE 350 Reporters
Intermediate Capital Group LON:ICP Full Year Results
Softcat LON:SCT Q2 Trading Statement
Pershing Square [LON:PSH] Q1 Results
Pets at Home LON:PETS Full Year Results
Salesforce NYSE:CRM Q1 Results
Auto Trader LON:AUTO Full Year Results
Bodycote LON:BOY AGM Trading Statement
Dr. Martens LON:DOCS Full Year Results
HarbourVest Global Private Equity [LON:HVPE] Full Year Results
No FTSE 350 Reporters

Looking for great investing ideas? Sign up to our free newsletter.

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

CME Group
FP Markets
Back To Top